Viewing nowBrivaracetam 10 mg Tablet
Brivaracetam 10mg
Tablet · Prescription medication
Myungin Pharmaceutical Co., Ltd.

MFDS item code 202502766 · Approved 2025.10.28
Adjunctive treatment of partial-onset seizures in patients with epilepsy aged 16 years and older
This medication is used as an adjunctive treatment for partial seizures in patients with epilepsy aged 16 and older. It is particularly effective in cases where secondary generalized seizures are present. Therefore, this medication helps reduce the frequency and intensity of seizures in patients with complex seizure forms. It contributes to the improvement of symptoms during the treatment process and can be used safely and effectively in combination with other antiepileptic drugs. Overall, it provides a positive effect in the management of epilepsy.
This drug is taken twice daily. The recommended initial dose is 25mg or 50mg per dose, based on the healthcare provider's assessment of potential adverse effects in relation to seizure reduction. Based on clinical response and tolerability, the dose may be increased or decreased from 50mg per day [25mg per dose, twice daily] to 200mg per day [100mg per dose, twice daily]. (Tablets) This drug is a film-coated tablet. Swallow it whole with water. It may be taken with or without food. If you miss a dose If you miss one or more doses, take one dose as soon as you remember, then take the next dose at the next scheduled morning or evening time. Discontinuation When discontinuing this drug, gradually reduce the dose by 50mg per day at 1-week intervals. After taking 50mg per day for 1 week, a dose of 20mg per day is recommended for the final week (see section ‘1. Warnings’). Elderly patients (65 years and older) No dosage adjustment is required in elderly patients. Clinical experience in elderly patients aged 65 years and older is limited. Renal impairment No dosage adjustment is required in patients with renal impairment. This drug is not recommended for patients with end-stage renal disease receiving hemodialysis. Hepatic impairment Exposure to this drug is increased in patients with hepatic impairment. The recommended initial dose for patients with hepatic impairment is 50mg per day [25mg per dose, twice daily], and the recommended maximum dose is 150mg per day [75mg per dose, twice daily].
This medication can cause severe mental health issues such as suicidal thoughts or behaviors; therefore, it is crucial to closely monitor for these symptoms during treatment. Central nervous system-related side effects, such as drowsiness, fatigue, and dizziness, may occur at the beginning of treatment or at any time during therapy; caution is needed when driving or operating machinery. This medication should not be abruptly discontinued, as seizures may worsen; dosage should be gradually reduced under the guidance of a physician. Patients who are allergic to this medication or similar components, or who have certain genetic disorders, should not take this drug. Patients with liver function issues may need dosage adjustments, and safety data for patients with liver impairment is limited. During the use of this medication, changes in mental state, such as depression, anxiety, or suicidal thoughts, should be closely monitored, and if serious side effects such as severe skin reactions occur, the medication should be discontinued immediately, and consultation with a physician is necessary. Alcohol consumption may exacerbate the side effects of this medication, so it is advisable to avoid taking them together. When taking this medication in conjunction with other drugs, interactions may occur, so all medications being taken should be disclosed to a physician or pharmacist. Women who are pregnant or planning to become pregnant should carefully consider the risks and benefits of taking this medication, and those who are breastfeeding should consult with a healthcare professional before deciding to take it. This medication should preferably not be used in children under 16, as its safety and efficacy has not been sufficiently established. If drowsiness or dizziness is severe, driving or operating hazardous machinery should be avoided. In case of overdose, as there is no specific antidote, seek immediate medical attention for appropriate treatment, and blood dialysis is not effective. This medication should be stored out of the reach of children, and transferring it to other containers should be avoided as it may lead to quality deterioration or accidents.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius to ensure the medication's efficacy is preserved for a long time.
White round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowBrivaracetam 10mg
Tablet · Prescription medication
Myungin Pharmaceutical Co., Ltd.
Brivaracetam 1g
Solution · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 10mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 25mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 50mg
Tablet · Prescription medication
UCB Korea Co., Ltd.
Brivaracetam 100mg
Tablet · Prescription medication
UCB Korea Co., Ltd.

Brivaracetam 10mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Brivaracetam 25mg
Tablet · Prescription medication
Daewoong Pharm. Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.